Effect of curcumin on visfatin and zinc-α2-glycoprotein in a rat model of non-alcoholic fatty liver disease
Acta cir. bras; 31 (11), 2016
Publication year: 2016
ABSTRACT PURPOSE:
To investigate the effect of curcumin on visfatin and zinc-α2-glycoprotein (ZAG) expression levels in rats with non-alcoholic fatty liver disease (NAFLD).METHODS:
Fifty-six male rats were randomly divided into a control group (n=16) and model group (n=40) and were fed on a normal diet or a high-fat diet, respectively. Equal volumes of sodium carboxymethyl cellulose (CMC) were intragastrically administered to the control group for 4 weeks. At the end of the 12th week, visfatin and ZAG protein expression levels were examined by immunohistochemistry. Visfatin mRNA levels were measured by semi-quantitative reverse transcription polymerase chain reaction.RESULTS:
Compared with the control group, the model group showed significantly increased expression of visfatin in liver tissue (P < 0.01) and significantly decreased expression of ZAG (P < 0.01). These effects were ameliorated by curcumin treatment.CONCLUSIONS:
Visfatin and zinc-α2-glycoprotein may be involved in the pathogenesis of NAFLD. Treatment of NAFLD in rats by curcumin may be mediated by the decrease of visfatin and the increase of non-alcoholic fatty liver disease.
Antiinflamatorios no Esteroideos/uso terapéutico, Curcumina/uso terapéutico, Ácidos Grasos/metabolismo, Nicotinamida Fosforribosiltransferasa/metabolismo, Enfermedad del Hígado Graso no Alcohólico/metabolismo, Proteínas de Plasma Seminal/metabolismo, Alanina Transaminasa/sangre, Antiinflamatorios no Esteroideos/administración & dosificación, Antioxidantes/administración & dosificación, Antioxidantes/uso terapéutico, Colesterol/sangre, Curcumina/administración & dosificación, Modelos Animales de Enfermedad, Evaluación Preclínica de Medicamentos, Hígado/patología, Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico, Distribución Aleatoria, Ratas Sprague-Dawley, Triglicéridos/sangre